Androcur Effects on Quality of Life
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Measure of Androcur Effects on Quality of Life at Prostate Cancer Patients|
- Quality of life change measured by SF-35 questionnaire [ Time Frame: Baseline, after 3, 6 and 12 month ]
|Study Start Date:||June 2008|
|Study Completion Date:||January 2010|
|Primary Completion Date:||January 2010 (Final data collection date for primary outcome measure)|
Drug: Cyproterone acetate (Androcur)
The study drug will be administered either as monotherapy or in combination with other interventions (surgical castration or LHRH analogue treatment).
Daily dosage as monotherapy: 200-300 mg cyproterone acetate. Daily dosage following surgical castration: 100-200 mg cyproterone acetate. Daily dosage in combination with an LHRH-analogue: 100-200 mg cyproterone acetate.
Administration period: 12 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00908674
|Many Locations, Hungary|
|Study Director:||Bayer Study Director||Bayer|